Table 4.
Mitochondrial Impact | Coronavirus Protein | Virus Type | Targeting gene, enzyme, and pathway | Reference |
---|---|---|---|---|
Mitochondrial Dynamics | ORF9b | SARS-CoV | DRP1, IFN-g, PCBP2, AIP4, MAVS signalling, TRAF3, and TRAF6 | Gordon et al., 2020a |
mtDNA Copy Number | – | SARS-CoV-2 | ROS, Ca2+ signaling | Valdes-Aguayo et al., 2021, Wiedmer et al., 2008 |
Mitochondrial Membrane Potential | ORF8a, nsp10 | SARS-CoV | ROS, caspase-3 activation, | Keng et al., 2006 |
Mitochondrial Structure, Size | ORF9b, ORF7a, ORF7b, ORF3b, ORF1ab | SARS-CoV | DRP1, MAVS, TRAF3 & TRAF6 | Freundt et al., 2009, Shi et al., 2014 |
Oxidative Stress | ORF7a, nsp5 (3C-like protease), Nucleocapsid, ORF3a | SARS-CoV-2 SARS-CoV |
Ap4A-hydrolase, ROS, NF-kB signalling, IL-1β | Chernyak et al., 2020, Lin et al., 2006, Zhang et al., 2007 |
Mitophagy | ORF9b, ORF10 | SARS-CoV-2 | DRP1, NIX | Li et al., 2022, Zhu et al., 2016 |
Antiviral Immunity | ORF9a | SARS-COV | MAVS, NLRP3 inflammasome pathway, IL-1β and IL-18 | Zhou et al., 2012 |
Mitochondrial Fusion | ORF9b | SARS-CoV-2 SARS-CoV |
DRP1, MFN1, MFN2, OPA1 | Alavi and Fuhrmann, 2013, Astuti and Ysrafil, , 2020, Shi et al., 2014 |
Mitochondrial Fission | ORF9b | SARS-CoV-2 SARS-CoV |
DRP1, FIS1, MFF, MiD49, Mid51 | Astuti and Ysrafil, , 2020, Shi et al., 2014 |